6-K - Evaxion Biotech A/S | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Evaxion Biotech A/S convened its annual general meeting for 16 April 2026 at 14:00 CEST, proposing adoption of the 2025 audited annual report, carrying forward the loss, re-election of four board members, election of Jens Bitsch-Nørhave as new board member, re-election of EY as auditor, and authorizations for warrants up to DKK 11,900,000 and convertible loan notes up to DKK 73,500,000 nominal shares without pre-emptive rights.

Key Takeaways

1AGM on 16 April 2026 at 14:00 CEST at Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark; record date 9 April 2026.

2Propose carry forward of 2025 loss to next year.

3Board proposals: re-elect Marianne Søgaard (chairman), Lars Holtug, Lars Aage Staal Wegner, Roberto Prego Pineda; elect Jens Bitsch-Nørhave.

4Re-elect EY Godkendt Revisionspartnerselskab (CVR 30 70 02 28) as auditor.

5Authorize warrants to board/exec/key employees for shares up to DKK 11,900,000 nominal value until 15 April 2029 at market price, no pre-emptive rights.

6Authorize convertible loan notes convertible to shares up to DKK 73,500,000 nominal value until 15 April 2031 at market price +/-10%, no pre-emptive rights.

7Current share capital DKK 104,252,689 (417,010,756 shares of DKK 0.25).

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Executive & Director Changes

Jens Bitsch-Nørhave

Board Member

Election

Proposed by board of directors

Exhibits (3)

6-K

FORM 6-K

99.1

EXHIBIT 99.1

99.2

EXHIBIT 99.2